Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Around the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

Department of Labor Wants to Study Possible Occupation-Cancer Links

February 1, 1995
Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 4 No 2
Volume 4
Issue 2

WASHINGTON--The US Department of Labor, Occupational Safety and Health Administration (OSHA) wants more money to study the possible associations between occupation and the incidence of cancer.

WASHINGTON--The US Department of Labor, Occupational Safety andHealth Administration (OSHA) wants more money to study the possibleassociations between occupation and the incidence of cancer.

Testifying before the President's Cancer Panel, Peter Infante,DDS, DrPH, director of OSHA's Office of Standards Review, saidthat OSHA needs the information to set the workplace standardfor permissible levels of certain substances believed to be carcinogens.

Dr. Infante said that 22 agents, proven carcinogenic by the WorldHealth Organization's International Agency for Research on Cancer(IARC), are still used in industry. In addition, 42 other industrialcompounds and agents are listed by the IARC as "probable"causes of human cancer on the basis of animal or epidemiologicevidence.

Articles in this issue

FTC Advised to List Tar and Nicotine Levels Directly on Cigarette Packages
Multidisciplinary Approach Urged For Pain Relief
FDA Approves New Indication for Neupogen: Chronic Neutropenia
Department of Labor Wants to Study Possible Occupation-Cancer Links
Undertreatment of Cancer-Related Pain May Be Tied to Physicians' Fear of Addiction to Drugs
Navelbine Is Now Available for Use in Inoperable Advanced Stage NSCLC
ASH Panel: How Many Hemotologists/Oncologists Are Enough?
Mammography Van Brings Breast Cancer Screening to the Workplace
FDA to Build $600 Million Campus
Finasteride Studied as Prostate Ca Preventive
Panel Fails to Recommend Taxotere as Treatment for Breast and Lung Cancer
Thrombopoietin Raises Platelet Counts in Animals
Major Cancer Centers Form Network to Negotiate With Insurers
ACS Panel on Prostate Cancer: Painful Skeletal Mets Require Special Management
Liposomal Tretinoin in Phase II/III Trials in Kaposi's Sarcoma Patients
Recent Videos
Patients with cancer are subjected to fewer radiotherapy-induced toxicities because of newer, more advanced technologies.
Hosts Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, discuss presentations at ESMO 2025 that may impact bladder, kidney, and prostate cancer care.
Mandating additional immunotherapy infusions may help replenish T cells and enhance tumor penetration for solid tumors, including GI malignancies.
A novel cancer database may assist patients determine what clinical trials they are eligible to enroll on and identify the next best steps for treatment.
Receiving information regarding tumor-associated antigens or mutational statuses from biopsies may help treatment selection in GI malignancies.
An easy-to-access database allows one to see a patient’s cancer stage, prior treatment, and survival outcomes in a single place.
Related Content
Advertisement

A significant survival improvement was observed among patients with dMMR carcinomas who received atezolizumab/chemotherapy.

Atezolizumab Combo Displays Noninferior Survival in Endometrial Cancer

Roman Fabbricatore
October 19th 2025
Article

A significant survival improvement was observed among patients with dMMR carcinomas who received atezolizumab/chemotherapy.


Experts highlight anticipated sessions at the 2025 ESMO Congress, including those on the PSMAddition and EV-303 trials.

Exploring the ESMO 2025 Presentations That May Shift GU Oncology

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
October 16th 2025
Podcast

Experts highlight anticipated sessions at the 2025 ESMO Congress, including those on the PSMAddition and EV-303 trials.


Data from the INTERCEPT study support ctDNA clearance as a useful end point for potential benefit in studies assessing novel therapeutics.

Adjuvant Therapy Confers Postoperative ctDNA Clearance, DFS Benefit in CRC

Russ Conroy
October 19th 2025
Article

Data from the INTERCEPT study support ctDNA clearance as a useful end point for potential benefit in studies assessing novel therapeutics.


Jorge Cortes, MD, outlines the impact of imatinib in chronic myeloid leukemia and highlights future initiatives in the field.

Charting the Evolution of TKIs and Finding the Next Breakthrough in CML

Jorge E. Cortes, MD
October 13th 2025
Podcast

Jorge Cortes, MD, outlines the impact of imatinib in chronic myeloid leukemia and highlights future initiatives in the field.


Capivasertib plus abiraterone show consistent benefits across clinical end points in the phase 3 CAPItello-281 trial.

Capivasertib Combo Improves rPFS in PTEN-Deficient HSPC Population

Silas Inman
October 19th 2025
Article

Capivasertib plus abiraterone show consistent benefits across clinical end points in the phase 3 CAPItello-281 trial.


Data from IDeate-Lung01 reveal a disease control rate exceeding 90% with infinatamab deruxtecan.

I-DXd Yields Promising Intracranial Efficacy in ES-SCLC Population

Kristi Rosa
October 19th 2025
Article

Data from IDeate-Lung01 reveal a disease control rate exceeding 90% with infinatamab deruxtecan.

Related Content
Advertisement

A significant survival improvement was observed among patients with dMMR carcinomas who received atezolizumab/chemotherapy.

Atezolizumab Combo Displays Noninferior Survival in Endometrial Cancer

Roman Fabbricatore
October 19th 2025
Article

A significant survival improvement was observed among patients with dMMR carcinomas who received atezolizumab/chemotherapy.


Experts highlight anticipated sessions at the 2025 ESMO Congress, including those on the PSMAddition and EV-303 trials.

Exploring the ESMO 2025 Presentations That May Shift GU Oncology

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
October 16th 2025
Podcast

Experts highlight anticipated sessions at the 2025 ESMO Congress, including those on the PSMAddition and EV-303 trials.


Data from the INTERCEPT study support ctDNA clearance as a useful end point for potential benefit in studies assessing novel therapeutics.

Adjuvant Therapy Confers Postoperative ctDNA Clearance, DFS Benefit in CRC

Russ Conroy
October 19th 2025
Article

Data from the INTERCEPT study support ctDNA clearance as a useful end point for potential benefit in studies assessing novel therapeutics.


Jorge Cortes, MD, outlines the impact of imatinib in chronic myeloid leukemia and highlights future initiatives in the field.

Charting the Evolution of TKIs and Finding the Next Breakthrough in CML

Jorge E. Cortes, MD
October 13th 2025
Podcast

Jorge Cortes, MD, outlines the impact of imatinib in chronic myeloid leukemia and highlights future initiatives in the field.


Capivasertib plus abiraterone show consistent benefits across clinical end points in the phase 3 CAPItello-281 trial.

Capivasertib Combo Improves rPFS in PTEN-Deficient HSPC Population

Silas Inman
October 19th 2025
Article

Capivasertib plus abiraterone show consistent benefits across clinical end points in the phase 3 CAPItello-281 trial.


Data from IDeate-Lung01 reveal a disease control rate exceeding 90% with infinatamab deruxtecan.

I-DXd Yields Promising Intracranial Efficacy in ES-SCLC Population

Kristi Rosa
October 19th 2025
Article

Data from IDeate-Lung01 reveal a disease control rate exceeding 90% with infinatamab deruxtecan.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.